The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Missouri

ChiCTR2400084087

/ SuspendedPhase 1IIT

Pre IVF/ICSI intake Omega 3 Fatty Acid in PCOS patients:A multicenter, randomized, double-blind, placebo-controlled clinical trial

Start Date01 Jun 2025

Sponsor / Collaborator-

ACTRN12625000336482

/ Not yet recruitingNot ApplicableIIT

The Effect of Mussel Consumption on Omega-3 Index and Recovery Markers in Female Endurance Athletes

Start Date01 May 2025

Sponsor / Collaborator

Deakin University

100 Clinical Results associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

100 Translational Medicine associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

100 Patents (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

5,047

Literatures (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

31 Dec 2025·Epigenetics

Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines

Article

Author: Kaul-Ghanekar, Ruchika ; Raina, Prerna ; Ulhe, Amrita ; Chaudhary, Amol

Cervical cancer, the fourth most common cancer globally and the second most prevalent cancer among women in India, is primarily caused by Human Papilloma Virus (HPV). The association of diet with cancer etiology and prevention has been well established and nutrition has been shown to regulate cancer through modulation of epigenetic markers. Dietary fatty acids, especially omega-3, reduce the risk of cancer by preventing or reversing the progression through a variety of cellular targets, including epigenetic regulation. In this work, we have evaluated the potential of ALA (α linolenic acid), an ω-3 fatty acid, to regulate cervical cancer through epigenetic mechanisms. The effect of ALA was evaluated on the regulation of histone deacetylases1, DNA methyltransferases 1, and 3b, and global DNA methylation by ELISA. RT-PCR was utilized to assess the expression of tumor regulatory genes (hTERT, DAPK, RARβ, and CDH1) and their promoter methylation in HeLa (HPV18-positive), SiHa (HPV16-positive) and C33a (HPV-negative) cervical cancer cell lines. ALA increased DNA demethylase, HMTs, and HATs while decreasing global DNA methylation, DNMT, HDMs, and HDACs mRNA expression/activity in all cervical cancer cell lines. ALA downregulated hTERT oncogene while upregulating the mRNA expression of TSGs (Tumor Suppressor Genes) CDH1, RARβ, and DAPK in all the cell lines. ALA reduced methylation in the 5' CpG island of CDH1, RARβ, and DAPK1 promoters and reduced global DNA methylation in cervical cancer cell lines. These results suggest that ALA regulates the growth of cervical cancer cells by targeting epigenetic markers, shedding light on its potential therapeutic role in cervical cancer management.

01 Aug 2025·MEAT SCIENCE

Utilizing flaxseed and microalgae (Nannochloropsis oculata; Great O Plus) to enhance beef omega-3 content: Effects on 90/10 round and 80/20 chuck ground beef patty fatty acid composition, color stability, and palatability

Article

Author: Nasiu, Firman ; Li, Xiaohan ; Alambarrio, Daniela A ; McKinney, Gina A ; Devane, Sarah A ; Gonzalez, John M ; Catrett, Cameron C ; Stelzleni, Alexander M ; Drouillard, James S

Many studies demonstrate boosting beef omega-3 content causes detrimental effects on product color stability and palatability. The study objective was to determine effects of feeding Great O Plus on ground beef fatty acid composition, color stability, and palatability. Ground Round (90/10) and Chuck (80/20) patties were produced from steers fed either a conventional finishing diet (CON;n = 14) or a conventional finishing diet containing a 10 % extruded proprietary flaxseed, wheat middling, and Nannochloropsis oculata algae blend (OMG; n = 14). To evaluate color stability, patties were displayed under retail conditions for 4 days with objective and subjective color measures collected every 12 h. Cooked patties were rated by both trained and consumer panels to evaluate palatability. Round and Chuck patties produced from steers fed Great O Plus increased (P < 0.01) alpha-linolenic acid content in both product types. Patties from the OMG treatment did not differ in color stability nor palatability measures when compared to CON patties (P < 0.15). When differences occurred, OMG patties had less visual discoloration, decreased lipid oxidation, and greater overall consumer palatability ratings (P < 0.09). While not directly measured in the present study, it is hypothesized the lack of detrimental effects on product color and palatability was due to a combination of the elevated antioxidant content of the Nannochloropsis oculata algae in Great O Plus and lack of measurable long-chain omega-3 fatty acid presence.

01 Aug 2025·NUTRITION

Omega-3 supplementation increases 13C-EPA but not 13C-DHA kinetics in healthy older adults after 13C-DHA single dose intake: A secondary analysis

Article

Author: Vachon, Annick ; Plourde, Mélanie ; Ku, David ; Loukil, Insaf ; Metherel, Adam

OBJECTIVE:

To investigated whether post supplementation, ¹³C-DHA is less incorporated into plasma phospholipids (PL) and triglycerides (TG) compared to pre-supplementation considering that these are the two most prominent delivery pools of DHA to tissues.

METHODOLOGY:

Plasma samples from twenty healthy men and women, matched for age and body mass index, were analyzed. Participants received a single oral dose of 40 mg ¹³C-DHA in 2 kinetic studies: 1 prior to and 1 during the last month of supplementation with 3.2 g/day of ω3 PUFA. ¹³C enrichment analyses were performed on plasma samples at baseline, 4, 6, 24 hours, 7 days, and 28 days post-tracer intake. Lipids were extracted, and PL and TG were separated by solid-phase extraction. Quantification of carbon-13 eicosapentaenoic acid (¹³C-EPA) and ¹³C-DHA was performed using gas chromatography-mass spectrometry (GC-MS).

RESULTS:

The area under the curve (AUC) for ¹³C-DHA in PL and TG did not show statistically significant differences before and during supplementation. However, the AUC for ¹³C-EPA in PL and TG increased by 45% and 48% with supplementation, respectively. This finding was unexpected, as our previous analysis indicated a 60% reduction in plasma ¹³C-DHA levels during supplementation, accompanied by increased β-oxidation. Additionally, there were statistically significant time × gender interactions for ¹³C-EPA and ¹³C-DHA in plasma PL (P < 0.0001), with women exhibiting 90% and 139% higher levels of ¹³C-EPA and ¹³C-DHA over time, respectively. No time × gender interactions were observed for ¹³C-EPA and ¹³C-DHA in plasma TG, although independent time and gender effects were present. Furthermore, there was a time × body mass index interaction for ¹³C-EPA in PL only.

CONCLUSION:

This secondary analysis suggests that after supplementation with ω3 PUFA, DHA metabolism is stable while EPA metabolism may be slowed due to factors such as DHA inhibition of EPA elongation and/or reduced plasma clearance, which may indicate the tissues needs for DHA are being met.

News (Medical) associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

07 Mar 2025

·www.prnewswire.com

TRANSFORM YOUR SKIN HEALTH: DIET AND LIFESTYLE TAKE CENTER STAGE AT 2025 AAD ANNUAL MEETING

ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the latest research on skin, hair, and nails, including topics on how diet and lifestyle can transform skin health, eczema management, and insights into aging skin. A New Era in Skin Health: GLP-1 Medications Your skin is often a window to your overall health, including underlying inflammatory and metabolic conditions. New treatments, like GLP-1 medications commonly used for weight loss, can help manage obesity, reduce inflammation, and improve skin conditions, highlighting how board-certified dermatologists are advancing personalized care. Inflammation and Skin Conditions Are Linked: Obesity often causes inflammation that can worsen or trigger skin conditions like psoriasis, eczema, and hidradenitis suppurativa, a chronic disease that causes painful lumps to form under the skin. GLP-1 Medications and Your Skin: While originally developed to treat diabetes and, more recently, promote weight loss, GLP-1 medications can reduce inflammation caused by obesity and improve certain skin conditions. A New Era of Dermatology: Treating conditions like obesity can bring about a healthier 'you' and help skin treatments work better, leading to more complete care. Lindsey Bordone, MD, FAAD, an assistant professor of dermatology at Columbia University Department of Dermatology, can discuss the connection between obesity and skin health, and how addressing your overall health can benefit your skin and well-being. The Role of Diet in Managing Eczema Many people believe that food is the root cause of atopic dermatitis, commonly known as eczema, which can result in dry, itchy skin. However, the relationship between diet and this common skin condition is more complex than it seems. New research is shedding light on how diet influences eczema – which affects nearly one in ten Americans – and empowers patients to make more informed choices. Cutting Foods Isn't a Cure-All: For most patients, simply eliminating certain foods doesn't significantly improve eczema symptoms, despite common misconceptions. The Role of a Healthy Diet: Emphasizing overall healthy eating and avoiding allergens can still play an important role in managing eczema. Early Allergen Introduction: Introducing allergenic foods early in life may help build tolerance, offering a powerful shift in how people manage their eczema. Peter A. Lio, MD, FAAD, a clinical assistant professor of dermatology at Northwestern Medicine in Chicago, can provide evidence-based strategies for managing eczema through diet and lifestyle. How Diet Can Enhance the Effectiveness of Skin Treatments The foods you eat play a vital role in how well medications work for skin conditions and can even help to minimize possible side effects. By making thoughtful dietary choices, you can support your skin health, maximize the effectiveness of treatments for skin disease, and improve your overall health. Optimize Treatment with Nutrition: The Mediterranean diet, which encourages people to eat plant-based foods, and omega-3 fats, can help make biologic treatments for psoriasis more effective, while also reducing heart disease risks associated with this common skin condition. Support Immunotherapy with Fiber: For advanced melanoma, the deadliest form of skin cancer, a diet rich in fiber from fruits, vegetables, and whole grains enhances the effectiveness of immunotherapy, a cancer treatment that uses the patient's own immune system to fight the disease. At the same time, patients should avoid probiotic supplements, which can make treatments less effective. Complement Therapy with Supplements: For those who suffer from acne, omega-3 supplements improve the absorption of isotretinoin, a common acne medication, and minimize its side effects. Steven Daveluy, MD, FAAD, an associate professor of dermatology at Wayne State University in Dearborn, Michigan, details how your diet can work alongside your treatment plan for healthier skin and a healthier you. Understanding Itch: A Window into Aging Skin Itch is the most common symptom for which patients over 50 visit a dermatologist. Importantly, recent scientific breakthroughs and treatment innovations are revolutionizing dermatologists' understanding and management of this condition. More than a symptom, itch offers valuable insights into how the immune system, nervous system, and skin barrier – the outermost layer of skin that serves as a protective shield for the body – change as we age. Increasingly More Common and Severe: Itch becomes more common and severe with age, significantly impacting quality of life, including sleep, daily activities, and our ability to care for others. Complicated Causes in Older Adults: Diagnosing the cause of itch in older adults is harder because visual signs and lab clues are less definitive. This can result in undertreatment. Evolving Treatments: While there are no FDA-approved medications specifically for itch, dermatologists have a variety of treatments at hand to address its effects, including moisturizers as well as topical ointments, phototherapy, biologics – which target diseases throughout your body and neurologic treatments like nerve creams and oral medications. Daniel C. Butler, MD, FAAD, an assistant dean and an associate professor of dermatology at University of Arizona College of Medicine in Tucson, can discuss the types of personalized treatment options dermatologists recommend for patients who struggle with persistent itch. If you have questions about a skin, hair, or nail condition, consult a board-certified dermatologist to ensure you receive trusted, expert guidance tailored to your needs. About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest, and YouTube, and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

19 Dec 2024

·www.businesswire.com

Marea Therapeutics Expands Management Team and Board of Directors

SAN FRANCISCO--( BUSINESS WIRE )--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors. “Momentum continues to build at Marea as we advance our lead program, MAR001, through clinical development,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “We are pleased to welcome Rebecca and Max to our leadership team and Robert to our board of directors. Their collective experience and expertise will be important as Marea enters its next phase of growth.” Rebecca Juliano, Ph.D., Appointed as Chief Development Officer Dr. Juliano has been in lipid-related research for more than 25 years and brings to Marea industry leadership experience across clinical program design, execution and communication. Most recently, Dr. Juliano served as chief operating officer at a stealth biotech startup, where she shaped teams and clinical programs for cardiovascular and rare disease indications. Prior to that, she led the clinical and related teams at Amarin Pharma, which were responsible for the cardiovascular outcomes trial REDUCE-IT, which received global approvals, led to changes in at least 15 global clinical guidelines, and received numerous accolades such as being named a top clinical trial by AHA, ACC and NEJM. Dr. Juliano began her industry career at Reliant Pharmaceuticals with the launch of Lovaza, and she has served multiple leadership and transitional consulting roles across her career. Prior to joining industry, Dr. Juliano was an AHA fellow at Weill Cornell Medical Center. She holds a Ph.D. from Columbia University and earned a B.S. in chemistry from the University of California, Santa Cruz. Max Zeiberg Appointed as Senior Vice President, Corporate Development Mr. Zeiberg most recently served as vice president, business development at Sana Biotechnology and at Graphite Bio, where he led partnering, strategic planning, and contributed to Graphite's Series B and IPO financings. Prior to that, Mr. Zeiberg held roles of increasing responsibility on the corporate development team at Gilead Sciences, culminating as head of virology partnering and M&A. During his time at Gilead, he successfully led numerous strategic transactions to build the company’s pipeline. Mr. Zeiberg began his career advising life science companies on commercial strategy and pipeline prioritization as a management consultant with ZS Associates. Mr. Zeiberg holds a B.S. in biomedical engineering from Columbia University and an MBA from the Kellogg School of Management at Northwestern University. Robert A. Harrington, M.D., Appointed to Board of Directors Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials. Dr. Harrington was the Arthur L. Bloomfield Professor and chair of the Department of Medicine at Stanford University for more than 10 years. He previously served as the Richard Stack Distinguished Professor and the director of the Duke Clinical Research Institute at Duke University, where he completed his fellowship in general and interventional cardiology. Dr. Harrington holds a Bachelor’s degree in English from the College of the Holy Cross and an M.D. from Tufts University School of Medicine. He served as chief resident during his residency in internal medicine at the University of Massachusetts Medical Center in Worcester. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X .

Executive ChangePhase 2

05 Nov 2024

·www.drugs.com

Fish Oil Supplements Might Help Prevent Cancer

TUESDAY, Nov. 5, 2024 -- The omega-3 and omega-6 fatty acids in fish oil supplements might help protect people from cancer , a new study claims. Study participants with higher levels of omega-3s had lower rates of colon , stomach, lung and other digestive tract cancers, researchers found. Likewise, high omega-6 levels led to lower rates of 14 different cancers, including brain, melanoma, bladder and more, result showed. “These findings suggest that the average person should focus on getting more of these fatty acids in their diets,” said lead researcher Yuchen Zhang , a doctoral student with the University of Georgia’s College of Public Health. The study relied on data from more than 253,000 participants in the UK Biobank research project. As part of that project, participants filled out dietary questionnaires and had their health tracked for decades. Of those people, nearly 30,000 developed some form of cancer, researchers said. Importantly, the benefits of high levels of fatty acids were independent of other cancer risk factors like BMI, alcohol use or physical activity. These fatty acids are present in fatty fish, nuts and plant-based cooking oils, but many people turn to fish oil supplements to make sure they’re getting enough. However, the benefits of these fatty acids aren’t universal. The researchers noted that high omega-3 levels could be associated with a slightly higher risk of prostate cancer. “For women, it’s an easy decision: Eat more omega-3,” researcher Kaixiong Ye , an associate professor in UGA’s Franklin College of Arts and Sciences, said in a university news release. The new study was published recently in the International Journal of Cancer . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Omega-3-acid ethyl esters(Trygg Pharma AS)

External Link

KEGG	Wiki	ATC	Drug Bank
D05255	Omega-3-acid ethyl esters(Trygg Pharma AS)	C10AX06	DB09539

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperlipidemias	Japan	Takeda Pharmaceutical Co., Ltd.	28 Sep 2012
Hyperlipoproteinemia Type I	Australia	Viatris Pty Ltd.	05 Aug 2010
Hypertriglyceridemia	United States	Waylis Therapeutics LLC	10 Nov 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipoproteinemia Type IV	Phase 3	China	AbbVie Pharmaceuticals GmbH	19 Sep 2016
Hyperlipoproteinemia Type IV	Phase 3	China	Pronova Biopharma Norge AS	19 Sep 2016
Hyperlipoproteinemia Type IV	Phase 3	China	Abbott Laboratories Trading (Shanghai) Co. Ltd.	19 Sep 2016
Hyperlipoproteinemia Type IV	Phase 3	China	GMPack ApS	19 Sep 2016
Hyperlipoproteinemia Type II	Phase 3	Norway	Pronova BioPharma ASA	01 Mar 2013
Cardiovascular Diseases	Phase 3	United States	BASF Corp.	01 Jul 2010
Cardiovascular Diseases	Phase 3	United States	Pronova BioPharma ASA	01 Jul 2010
Neoplasms	Phase 3	United States	BASF Corp.	01 Jul 2010
Neoplasms	Phase 3	United States	Pronova BioPharma ASA	01 Jul 2010
Heart Failure	Phase 3	United States	GSK Plc	01 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04181593 (CTgov)	Phase 3	Dry Eye Syndromes	322	Omega 3 fatty acid (OmegaD)	accwogrqjn(xzrxwlaack) = afgfwdgvfz paolajczlj (tedihlhgek, 17.1) View more	-	29 Jul 2024
				Placebos (Placebo)	accwogrqjn(xzrxwlaack) = rndjkkleik paolajczlj (tedihlhgek, 13.2) View more
ENDO2024	Not Applicable	Hypertriglyceridemia	-	Lovaza 2gm AM and 2gm PM	spzbyfywoc(ydmjgfroqu) = xhitvowowz gsnbetljrv (yxlgfudoaz )	-	01 Jun 2024
				Synthroid 220 mcg IV daily	spzbyfywoc(ydmjgfroqu) = jfrdltfxam gsnbetljrv (yxlgfudoaz )
NCT00746811 (CTgov)	Phase 4	Primary hypercholesterolemia	32	P-OM3 (P-OM3)	kfwuiwbenq(lkotjiixim) = rkylxoogif ckrbfbepjm (ahftpmyssm, 1.8) View more	-	08 May 2024
				Placebo (Placebo)	kfwuiwbenq(lkotjiixim) = ewgnsymkwm ckrbfbepjm (ahftpmyssm, 1.6) View more
AASLD2023	Not Applicable	-	-	Fenofibrate	vovstgwsfa(vnuleajzbx) = ejrxpwitvl ryafdiozgf (jdncuhljio ) View more	-	10 Nov 2023
				Bezafibrate	vovstgwsfa(vnuleajzbx) = izpfncuynq ryafdiozgf (jdncuhljio ) View more
NCT04198805 (PUVENAFLD, CTgov)	Phase 2	Nonalcoholic Steatohepatitis	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	xkxerkylhf(mpabfgbdqp) = aqlaqnurcy mguhmhphvj (jblatgfdbg, 26.4) View more	-	25 May 2023
				Placebo (Placebo)	xkxerkylhf(mpabfgbdqp) = mwfljubzbq mguhmhphvj (jblatgfdbg, 18.2) View more
NCT03345550 (OPTIMA, CTgov)	Phase 2	Brain Concussion	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	sxqamdhdvg(myacfktmxa) = kckssqhnll kmzzzpcxjz (hpavpdpvpu, kvscligxvd - dwfvrsucme) View more	-	23 May 2023
				Placebo - Cap (Placebo Arm)	sxqamdhdvg(myacfktmxa) = xvpoeqmitd kmzzzpcxjz (hpavpdpvpu, jkbjxscodp - ueqzaxxnfx) View more
NCT01669915 (VITAL-Cog, CTgov)	Not Applicable	Cognitive Dysfunction	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	zhrrqzkrpq(fokgazoiss) = fbgsaeabrv mvyhbcwruq (gpyusmeimo, 0.01) View more	-	21 Apr 2023
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	zhrrqzkrpq(fokgazoiss) = aqvadjekgg mvyhbcwruq (gpyusmeimo, 0.01) View more
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed \| Scand J Clin Lab Invest)	Phase 3	Hyperlipoproteinemia Type II	34	Omega-3 polyunsaturated fatty acid supplement	wgxxxjyfsu(xcgpidipwb) = uykhvmyqid rkjankoqxr (rgpwjnetwg, [ - 13, 6])	-	31 Mar 2023
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	Not Applicable	-	18,353	Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo)	jshdbukuev(inlbeqpgts) = txdmrawqtv jxtszhfajv (vpvmmrlmha, ngrhiqygrs - dyybqjtdxf) View more	-	14 Mar 2023
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	jshdbukuev(inlbeqpgts) = bftqnxbpjl jxtszhfajv (vpvmmrlmha, ssltwmbphy - xkeikyglus) View more
NCT04495816 (CTgov)	Phase 2	COVID-19 \| Anosmia	139	Omega-3 Fatty Acid Supplement (Omega-3)	krjrxxmpvf(qfbljgigbc) = hstfoqlhva ngxzfqncfq (rrenjtkfce, 1.94) View more	-	31 Jan 2023
				Placebo/Control (Placebo/Control)	krjrxxmpvf(qfbljgigbc) = ureostyefj ngxzfqncfq (rrenjtkfce, 1.88) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Omega-3-acid ethyl esters(Trygg Pharma AS)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation